cisapride has been researched along with Gallstone Disease in 8 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Gallbladder contractility, measured in vitro in response to CCK, decreased 23% in animals on the 1% cholesterol diet; cisapride restored the CCK dose-response curve to normal." | 5.29 | Cisapride improves gallbladder contractility and bile lipid composition in an animal model of gallstone disease. ( Shaffer, EA; Xu, QW, 1993) |
| " We studied the effect of cisapride, a prokinetic drug, on gallbladder emptying and bile composition in patients with gallstone disease undergoing cholecystectomy." | 5.09 | Cisapride improves gallbladder emptying and bile lipid composition in patients with gallstones. ( Chawla, Y; Dhiman, RK; Gupta, S; Kohli, KK; Reddi, R; Sharma, A; Singh, R; Suri, S, 2001) |
| "A randomised, double blind, placebo controlled, crossover design was used to examine the effects of cisapride (10 mg four times daily) on gall bladder emptying, mouth to caecum and large bowel transit times, and the proportions of deoxycholic acid and other bile acids, in fasting serum from: (i) control subjects (n=6), (ii) acromegalic patients not treated with octreotide (n=6), (iii) acromegalics on long term octreotide (n=8), and (iv) patients with constipation (n=8)." | 5.09 | Effects of cisapride on gall bladder emptying, intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial. ( Besser, GM; Dowling, RH; Jenkins, PJ; Malcolm, P; Mallet, AI; Murphy, GM; Veysey, MJ, 2001) |
| "Cholelithiasis affects 10-15% of the adult population in Western society, and about 75% of gallstones are of cholesterol type." | 2.39 | Cholesterol gallstone formation in man and potential treatments of the gallbladder motility defect. ( Palasciano, G; Portincasa, P; Stolk, MF; van Berge-Henegouwen, GP; van Erpecum, KJ, 1995) |
| "Dyspepsia affects one in four Australians; of those who present in general practice, the majority will have functional or non-ulcer dyspepsia, with no structural explanation for their symptoms." | 2.39 | Modern management of dyspepsia. ( Talley, NJ, 1996) |
| " Gallbladder contractility, measured in vitro in response to CCK, decreased 23% in animals on the 1% cholesterol diet; cisapride restored the CCK dose-response curve to normal." | 1.29 | Cisapride improves gallbladder contractility and bile lipid composition in an animal model of gallstone disease. ( Shaffer, EA; Xu, QW, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (75.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thorens, J | 1 |
| Schnegg, JF | 1 |
| Brignoli, R | 1 |
| Froehlich, F | 1 |
| Jansen, JB | 1 |
| Dorta, G | 1 |
| Blum, AL | 1 |
| Gonvers, JJ | 1 |
| Fried, M | 1 |
| Ziegenhagen, DJ | 1 |
| Heitz, W | 1 |
| Kruis, W | 1 |
| Pohl, C | 1 |
| Zehnter, E | 1 |
| Wenzl, H | 1 |
| Pristautz, H | 1 |
| Schreiber, F | 1 |
| Krejs, GJ | 1 |
| Xu, QW | 1 |
| Shaffer, EA | 1 |
| Portincasa, P | 1 |
| Stolk, MF | 1 |
| van Erpecum, KJ | 1 |
| Palasciano, G | 1 |
| van Berge-Henegouwen, GP | 1 |
| Talley, NJ | 1 |
| Dhiman, RK | 1 |
| Reddi, R | 1 |
| Sharma, A | 1 |
| Singh, R | 1 |
| Kohli, KK | 1 |
| Gupta, S | 1 |
| Suri, S | 1 |
| Chawla, Y | 1 |
| Veysey, MJ | 1 |
| Malcolm, P | 1 |
| Mallet, AI | 1 |
| Jenkins, PJ | 1 |
| Besser, GM | 1 |
| Murphy, GM | 1 |
| Dowling, RH | 1 |
2 reviews available for cisapride and Gallstone Disease
| Article | Year |
|---|---|
Cholesterol gallstone formation in man and potential treatments of the gallbladder motility defect.
Topics: Adult; Animals; Anti-Bacterial Agents; Cholelithiasis; Cholesterol; Cisapride; Crystallization; Fema | 1995 |
Modern management of dyspepsia.
Topics: Adult; Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Child; C | 1996 |
4 trials available for cisapride and Gallstone Disease
| Article | Year |
|---|---|
Effect of cisapride on gallbladder motility after extracorporeal shock-wave lithotripsy.
Topics: Adult; Aged; Cholecystokinin; Cholelithiasis; Cisapride; Cross-Over Studies; Double-Blind Method; Fe | 1995 |
[Effect of cisapride on clearance of gallstone fragments after extracorporeal shockwave lithotripsy of gallstones].
Topics: Administration, Oral; Adult; Anti-Ulcer Agents; Chenodeoxycholic Acid; Cholelithiasis; Cisapride; Co | 1994 |
Cisapride improves gallbladder emptying and bile lipid composition in patients with gallstones.
Topics: Adult; Bile; Cholecystectomy; Cholelithiasis; Cisapride; Female; Gallbladder Emptying; Gastrointesti | 2001 |
Effects of cisapride on gall bladder emptying, intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial.
Topics: Acromegaly; Adult; Cholelithiasis; Cholic Acid; Cisapride; Constipation; Cross-Over Studies; Deoxych | 2001 |
2 other studies available for cisapride and Gallstone Disease
| Article | Year |
|---|---|
Cisapride increases gallbladder volume in gallstone patients before and after extracorporeal shock wave lithotripsy.
Topics: Administration, Oral; Adult; Aged; Cholelithiasis; Cisapride; Female; Gallbladder; Humans; Lithotrip | 1993 |
Cisapride improves gallbladder contractility and bile lipid composition in an animal model of gallstone disease.
Topics: Animals; Bile; Bile Acids and Salts; Carbon Radioisotopes; Cholecystokinin; Cholelithiasis; Choleste | 1993 |